MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
0.3204
+0.0025
+0.79%
After Hours: 0.3202 -0.0002 -0.06% 18:27 09/11 EDT
OPEN
0.3242
PREV CLOSE
0.3179
HIGH
0.3250
LOW
0.3055
VOLUME
873.12K
TURNOVER
--
52 WEEK HIGH
2.570
52 WEEK LOW
0.3055
MARKET CAP
21.72M
P/E (TTM)
-0.3536
1D
5D
1M
3M
1Y
5Y
1D
TScan Therapeutics Launches Executive Retention Incentive Program
TipRanks · 1d ago
TScan Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 4d ago
TScan Therapeutics Price Target Cut to $1.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
Benzinga · 4d ago
TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 4d ago
Weekly Report: what happened at TCRX last week (0831-0904)?
Weekly Report · 5d ago
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
NASDAQ · 09/04 14:09
TScan Therapeutics Price Target Cut to $1.00/Share From $5.00 by Wedbush
Dow Jones · 09/03 13:19
More
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its hematologic malignancies and autoimmune programs. Its construct consists of two proprietary components: dual-targeting antibodies that direct the virus to cytotoxic and helper T-cells and mediate T cell activation, and a non-targeting fusogen that mediates entry exclusively to T-cells. Its hematology program is designed to address patients who are diagnosed with hematologic malignancies and can benefit from undergoing allogeneic transplantation. Its TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45.

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.